Evotec SE Sponsored ADR (EVO)
Evotec Q2 Earnings Call Highlights
Evotec NASDAQ: EVO reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements.
Evommune's Healthy Balance Sheet Buys Them Time For AD
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.
Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Christian Wojczewski - CEO & Management Board Member Cord Dohrmann - Chief Scientific Officer & Member of Management Board Paul Hitchin - CFO & Member of Management Board Volker Braun - Executive VP and Head of Global Investor Relations & ESG Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Charles Robert Weston - RBC Capital Markets, Research Division Christian Ehmann - Warburg Research GmbH Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division Fynn Scherzler - Deutsche Bank AG, Research Division Joseph Hedden - Rx Securities Limited, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Operator Ladies and gentlemen, welcome to the Evotec SE Half Year Report 2025 Conference Call.
Evotec SE (EVO) Q4 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Aurélie Dalbiez - Chief People Officer Conference Call Participants Christian Ehmann - Warburg Research Michael Ryskin - Bank of America Charles Weston - RBC Capital Markets Brendan Smith - TD Cowen Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Full-Year Result 2024 Analyst Call. I am Yusuf, the Chorus Call operator.
Evotec: Some Recovery Has Come, But Much More Is Expected
Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside.
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.
Evotec Announces Change in Management Board
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS.
Comment on Withdrawn Non-Binding Offer
HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.
Halozyme withdraws $2.1 bln buyout offer for Evotec
Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.
Halozyme CEO: Evotec Is Poised for Growth
Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.
